Brainsway yesterday priced its initial public offering in the U.S. slightly below the terms it set earlier this month.
The Jerusalem-based company, which is already publicly traded in Israel, said April 3 that it planned to float 2.5 million American Depository shares at roughly $11.94 apiece. Each ADS is would represent two ordinary shares, slated to begin trading today on the NASDAQ exchange under the “BWAY” symbol. Brainsway developed a transcranial magnetic stimulation device to treat psychological disorders.
Yesterday the company said it still plans to float 2.5 million ADS, but at the lower price of $11 apiece, for gross proceeds of $27.5 million. Another $4.1 million is on the table in the form of a 30-day underwriters option for 375,000 more shares, the company said.
Cantor Fitzgerald is the book-runner for the deal, with Raymond James and Oppenheimer as co-runners and Ladenburg Thalmann as co-manager, Brainsway said.
Last August, Brainsway won FDA de novo approval for its deep transcranial magnetic stimulation system with indications for treating obsessive compulsive disorder.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.